short free-peptide half-life favors brief, localized signaling rather than sustained systemic exposure Target: IGF-1 receptor (IGF1R)
She was hospitalized in August after suffering from vomiting, nausea, difficulty swallowing, rectal bleeding and abdominal pain
While RCTs are ongoing to further investigate GLP-1 and GLP-1/GIP RA agents as adjunct therapy for people with T1D, access to these drugs is already possible, based on their use to treat overweight and obesity
This program is not intended to diagnose, treat, cure, or prevent any disease
Artificial Sweeteners Gut Disruptors Sucralose, aspartame, and acesulfame potassium may disrupt gut bacteria and affect the gut-brain axis a system already impacted by GLP-1 medications